AssetMark’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$337 Hold
22
– – ﹤0.01% 3519
2026
Q2
$407 Buy
+22
New +$348 ﹤0.01% 3320

Other funds holding AVTX

AssetMark's AVTX Position: Q3 2026 in Review

AssetMark held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 22 shares worth $337. The position accounts for ﹤0.01% of the portfolio, ranked #3519.

AssetMark first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $407 in Q2 2026. 88 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • AssetMark held 22 shares of Avalo Therapeutics worth $337 as of Q3 2026.
  • AssetMark left its Avalo Therapeutics share count unchanged in Q3 2026.
  • Avalo Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3519 holding.
  • AssetMark first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • AssetMark's Avalo Therapeutics position peaked at $407 in Q2 2026.
  • 88 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.